Shares of Telix Pharmaceuticals (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.
The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.
The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.
The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.